Overview

• Blood tests detecting eMTBR-tau243 and crystalized tau proteins show over 90% accuracy in identifying Alzheimer’s progression and cognitive decline.
• The tests could guide early use of treatments like donanemab and lecanemab, which are most effective in early-stage Alzheimer’s patients.
• Researchers emphasize the potential of these tests to accelerate drug development by providing non-invasive ways to track disease biomarkers during clinical trials.
• Despite their promise, these blood tests require specialized laboratory methods and further validation before becoming widely available for routine clinical use.
• Experts highlight the need for cost-effective and accessible diagnostics to integrate these advancements into healthcare systems globally.